Big Pharma Valuation
| PRM Stock | CAD 13.12 0.01 0.08% |
At this time, the firm appears to be undervalued. Big Pharma Split shows a prevailing Real Value of C$15.24 per share. The current price of the firm is C$13.12. Our model approximates the value of Big Pharma Split from analyzing the firm fundamentals such as profit margin of (2.01) %, and Return On Equity of -0.0363 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Big Pharma's valuation include:
Price Book 0.9376 | Enterprise Value -9.4 M | Enterprise Value Ebitda (2.45) | Price Sales 46.2379 | Trailing PE 13.2525 |
Undervalued
Today
Please note that Big Pharma's price fluctuation is very steady at this time. Calculation of the real value of Big Pharma Split is based on 3 months time horizon. Increasing Big Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Big Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Big Stock. However, Big Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 13.12 | Real 15.24 | Hype 13.12 | Naive 13.21 |
The intrinsic value of Big Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Big Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Big Pharma Split helps investors to forecast how Big stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Big Pharma more accurately as focusing exclusively on Big Pharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Big Pharma's intrinsic value based on its ongoing forecasts of Big Pharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Big Pharma's closest peers.
Big Pharma Cash |
|
Big Valuation Trend
Knowing Big Pharma's actual value is paramount for traders when making sound investment determinations. Using both Big Pharma's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Big Pharma Total Value Analysis
Big Pharma Split is at this time expected to have takeover price of (9.41 M) with market capitalization of 14.83 M, debt of 10.3 M, and cash on hands of . The negative valuation of Big Pharma may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should thoroughly investigate all of the Big Pharma fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(9.41 M) | 14.83 M | 10.3 M |
Big Pharma Investor Information
The company has price-to-book ratio of 0.94. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Big Pharma Split last dividend was issued on the 28th of June 2024. Based on the key measurements obtained from Big Pharma's financial statements, Big Pharma Split is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Big Pharma Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The recent return on assets of Big suggests not a very effective usage of assets in November.Big Pharma Profitability Analysis
The company reported the revenue of 311.76 K. Net Loss for the year was (645.35 K) with profit before overhead, payroll, taxes, and interest of 5.56 M.Big Pharma Past Distributions to stockholders
About Big Pharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Big Pharma Split. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Big Pharma Split based exclusively on its fundamental and basic technical indicators. By analyzing Big Pharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Big Pharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Big Pharma. We calculate exposure to Big Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Big Pharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 311.8 K | 296.2 K | |
| Pretax Profit Margin | (2.07) | (1.97) | |
| Operating Profit Margin | (0.45) | (0.43) | |
| Net Loss | (0.45) | (0.43) | |
| Gross Profit Margin | 1.03 | 0.70 |
Other Information on Investing in Big Stock
Big Pharma financial ratios help investors to determine whether Big Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Big with respect to the benefits of owning Big Pharma security.